Literature DB >> 31362930

Microenvironmental Metabolism Regulates Antitumor Immunity.

Verra M Ngwa1, Deanna N Edwards2, Mary Philip1,3,4,5, Jin Chen6,2,4,7,8.   

Abstract

Metabolic reprogramming of cancer cells and the tumor microenvironment are emerging as key factors governing tumor growth, metastasis, and response to therapies including immune checkpoint inhibitors. It has been recognized that rapidly proliferating cancer cells, tumor-infiltrating lymphocytes, and vascular endothelial cells compete for oxygen and nutrients. Tumor cells and other cell types in the microenvironment not only compete for nutrients, but they also simultaneously produce immunosuppressive metabolites, leading to immune escape. In addition, commensal microbial metabolites can influence regulatory T cells and inflammation in the intestine, thus playing an essential role in cancer prevention or cancer promotion. In this review, we summarize recent advances on metabolic interactions among various cell types in the tumor microenvironment, with a focus on how these interactions affect tumor immunity. We also discuss the potential role of blood vessel metabolism in regulating immune cell trafficking and activation. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2019        PMID: 31362930      PMCID: PMC6697577          DOI: 10.1158/0008-5472.CAN-19-0617

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  73 in total

1.  Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation.

Authors:  Divya Vats; Lata Mukundan; Justin I Odegaard; Lina Zhang; Kristi L Smith; Christine R Morel; Roger A Wagner; David R Greaves; Peter J Murray; Ajay Chawla
Journal:  Cell Metab       Date:  2006-07       Impact factor: 27.287

Review 2.  High interstitial fluid pressure - an obstacle in cancer therapy.

Authors:  Carl-Henrik Heldin; Kristofer Rubin; Kristian Pietras; Arne Ostman
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

3.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.

Authors:  Ronald J Buckanovich; Andrea Facciabene; Sarah Kim; Fabian Benencia; Dimitra Sasaroli; Klara Balint; Dionysios Katsaros; Anne O'Brien-Jenkins; Phyllis A Gimotty; George Coukos
Journal:  Nat Med       Date:  2008-01-06       Impact factor: 53.440

4.  Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells.

Authors:  Candace M Cham; Gregory Driessens; James P O'Keefe; Thomas F Gajewski
Journal:  Eur J Immunol       Date:  2008-09       Impact factor: 5.532

5.  Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.

Authors:  Rakesh K Jain; Ricky T Tong; Lance L Munn
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

6.  Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis.

Authors:  Daniel K Nomura; Jonathan Z Long; Sherry Niessen; Heather S Hoover; Shu-Wing Ng; Benjamin F Cravatt
Journal:  Cell       Date:  2010-01-08       Impact factor: 41.582

Review 7.  Mini-review: overcoming tumor-intrinsic resistance to immune effector function.

Authors:  Ruth Ganss; Bernd Arnold; Günter J Hämmerling
Journal:  Eur J Immunol       Date:  2004-10       Impact factor: 5.532

8.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

9.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

Review 10.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

View more
  24 in total

1.  Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer.

Authors:  Deanna N Edwards; Verra M Ngwa; Ariel L Raybuck; Shan Wang; Yoonha Hwang; Laura C Kim; Sung Hoon Cho; Yeeun Paik; Qingfei Wang; Siyuan Zhang; H Charles Manning; Jeffrey C Rathmell; Rebecca S Cook; Mark R Boothby; Jin Chen
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

2.  A novel risk model based on immune response predicts clinical outcomes and characterizes immunophenotypes in triple-negative breast cancer.

Authors:  Xunxi Lu; Zongchao Gou; Luoting Yu; Hong Bu
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

3.  The Immunological Contribution of a Novel Metabolism-Related Signature to the Prognosis and Anti-Tumor Immunity in Cervical Cancer.

Authors:  Sihui Yu; Xi Li; Mingjun Ma; Rui Yang; Jiawen Zhang; Sufang Wu
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

4.  The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.

Authors:  Yilin Guo; Yangyang Bai; Lu Wang; Zhen Xu; Xiliang Wang; Wuliang Wang
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

5.  Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.

Authors:  M Nieves Calvo-Vidal; Nahuel Zamponi; Jan Krumsiek; Max A Stockslager; Maria V Revuelta; Jude M Phillip; Rossella Marullo; Ekaterina Tikhonova; Nikita Kotlov; Jayeshkumar Patel; Shao Ning Yang; Lucy Yang; Tony Taldone; Catherine Thieblemont; John P Leonard; Peter Martin; Giorgio Inghirami; Gabriela Chiosis; Scott R Manalis; Leandro Cerchietti
Journal:  Cancer Res       Date:  2021-09-03       Impact factor: 12.701

6.  Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth.

Authors:  Yuyi Wang; Ombretta Salvucci; Hidetaka Ohnuki; Andy D Tran; Taekyu Ha; Jing-Xin Feng; Michael DiPrima; Hyeongil Kwak; Dunrui Wang; Yanlin Yu; Michael Kruhlak; Giovanna Tosato
Journal:  EMBO Mol Med       Date:  2021-06-08       Impact factor: 12.137

7.  Metabolic and Immunological Subtypes of Esophageal Cancer Reveal Potential Therapeutic Opportunities.

Authors:  Ryan J King; Fang Qiu; Fang Yu; Pankaj K Singh
Journal:  Front Cell Dev Biol       Date:  2021-07-08

8.  Significance of N6-Methyladenosine RNA Methylation Regulators in Immune Infiltrates of Ovarian Cancer.

Authors:  Jing Gu; Fangfang Bi
Journal:  Front Genet       Date:  2021-07-07       Impact factor: 4.599

9.  Molecular subtype identification and prognosis stratification by a metabolism-related gene expression signature in colorectal cancer.

Authors:  Dagui Lin; Wenhua Fan; Rongxin Zhang; Enen Zhao; Pansong Li; Wenhao Zhou; Jianhong Peng; Liren Li
Journal:  J Transl Med       Date:  2021-06-30       Impact factor: 5.531

10.  Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by upregulating monocyte/macrophage infiltration into the clear cell renal cell carcinoma microenvironment.

Authors:  Wenhao Xu; Wang-Rui Liu; Yue Xu; Xi Tian; Aihetaimujiang Anwaier; Jia-Qi Su; Wen-Kai Zhu; Guo-Hai Shi; Gao-Meng Wei; Yong-Ping Huang; Yuan-Yuan Qu; Hai-Liang Zhang; Ding-Wei Ye
Journal:  Int J Biol Sci       Date:  2021-06-01       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.